FZD4 and neoplasm: Even though challenges like tissue specificity, delivery, and overcoming tumor heterogeneity remain, the combination of advanced antibody engineering, structural insights, and creative antigen design is significantly accelerating the clinical translation of GPCR‐targeted mAbs.